Stock DMAC DIAMEDICA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
3.2 USD +6.67% Intraday chart for DiaMedica Therapeutics Inc. +10.73% +12.68%
Jul. 01 DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding CI
Jun. 27 Transcript : DiaMedica Therapeutics Inc. - Special Call

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
BU
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
BU
DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding
CI
DiaMedica Therapeutics Announces Expansion of DM199 Program into Preeclampsia
AQ
Transcript : DiaMedica Therapeutics Inc. - Special Call
DiaMedica Therapeutics Announces $11.8 Million Private Placement
BU
DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia
CI
 DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
BU
DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding
CI
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director
CI
Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
BU
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
BU
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment
MT
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
BU
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
CI
DiaMedica Therapeutics Inc. Announces Executive Changes
CI
DiaMedica Therapeutics Files $100 Million Mixed Shelf
MT
Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. News DiaMedica Therapeutics Inc.